output publications or other works AB0237 WHAT DO SPANISH RHEUMATOLOGISTS THINK ABOUT THE EFFICACY OF THE DRUGS USED IN THE MANAGEMENT OF PATIENT WITH RHEUMATOID ARTHRITIS AND POOR PROGNOSIS FACTORS? PROGRESAR-2 PROJECT Conference Poster AB0319 -ABATACEPT IN RHEUMATOID ARTHRITIS WITH INTERSTITIAL LUNG DISEASE. A MULTICENTRE STUDY OF 181 PATIENTS Conference Poster AB0473 Hypogammaglobulinemia and infections in rheumatologic patients treated with rituximab. Conference Poster AB0473. Hypogammaglobulinemia and infections in rheumatologic patients treated with rituximab. Conference Poster AB0577 TOCILIZUMAB IN GIANT CELL ARTERITIS. ROUTE OF ADMINISTRACION: INTRAVENOUS OR SUBCUTANEOUS Conference Poster AB0858. MAINLY MEN, AND OLDER PEOPLE, WITH FRAGILITY HIP FRACTURE DO NOT RECEIVE ANTIOSTEOPOROTIC TREATMENT Conference Poster AB0865. Gout in hospitalised patients for cardiovascular diseases: prevalence and management status. Conference Poster FRI0146 SURVIVAL OF JAK INHIBITORS: REAL-WORLD DATA FROM THE BIOBADASER III REGISTRY Conference Poster FRI0276 TIME OF DISEASE EVOLUTION AND EFFICACY OF TOCILIZUMAB IN GIANT CELL ARTERITIS Conference Poster FRI0277 ISCHEMIC AND SYSTEMIC SYMPTOMS IN GIANT CELL ARTERITIS PATIENTS, RESPONSE TO TOCILIZUMAB Conference Poster FRI0692. Human papilloma virus screening and chronic inflammatory arthritis: an audit. Conference Poster HORMONE DEPENDENCE AND CANCER IN SYSTEMIC LUPUS ERYTHEMATOSUS Conference Poster OBESITY AND RISK OF FRACTURE: DEPENDS ON THE BODY MASS INDEX AND TYPE OF FRACTURE Conference Paper OP0124 Do all antiphospholipid antibodies confer the same risk for major organ involvement in SLE patients? Conference Paper OP0249. Antiphospholipid syndrome (aps) in systemic lupus erythematosus (sle) leads to a more severe disease. Conference Paper OP0339 TOCILIZUMAB IN GIANT CELL ARTERITIS. MONOTHERAPY VERSUS COMBINED WITH CONVENTIONAL IMMUNOSUPPRESSIVE DRUGS Conference Paper RESPONSE TO BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITISWITH FAILURE TO CONVENTIONAL SYNTHETIC DMARD AND/OR BIOLOGICAL DMARD: DATA FROM A LOCAL REGISTRY Conference Paper RISK OF HOSPITAL ADMISSION DUE TO INFECTION IN PATIENTS UNDERGOING TREATMENT WITH BIOLOGICAL THERAPY: CASE-CONTROL STUDY Conference Paper SAT0159 CHANGING PATTERN OF THE USE OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS Conference Poster SAT0168 Impact of age on the appearance of adverse eventsat the beginning of biological treatment: data from the BIOBADASER 3.0 registry. Conference Poster SAT0199. Polyautoimmunity in systemic lupus erythematosus. Data from a large Spanish cohort: Spanish society of rheumatology registry of patients with systemic lupus erythematosus (RELESSER). Conference Poster SAT0219 EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS INDEPENDENTLY OF THE INICIAL PREDNISONE DOSE Conference Poster SAT0386 Prevalence of subclinical cardiovascular disease in psoriatic arthritis: a multicentric study. Conference Poster SAT0441. Skin adverse events with febuxostat in gout patientswith previous skin reactions to allopurinol. A multicentre descriptive study. Conference Poster SAT0442. Calcium pyrophosphate crystal arthritis during hospitalizations: a prospective, crystal-proven case series. Conference Poster SAT0616 DIETARY HABITS OF SIX AUTOIMMUNE DISEASES IN THE SPANISH POPULATION: A CROSS-SECTIONAL STUDY Conference Poster
